Compare Amphastar Pharmaceuticals Inc (AMPH) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs WD 40 Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while WD 40 Company trades at $233.59 (market cap $3.15B). The key difference: WD 40 Company is far larger — about 3.6× Amphastar Pharmaceuticals Inc's market cap, and WD 40 Company pays a 1.74% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | WDFC | |
|---|---|---|
Market Cap | $863.95M | $3.15B |
Sector | Health | Technology |
52-Week High | $30.81 | $264.91 |
52-Week Low | $16.87 | $187.52 |
Enterprise Value | $1.26B | $3.20B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
WDFC trades at $234.93, up 1.61% today, with a bullish technical outlook supported by moving averages but neutral oscillators. Recent Q2 2026 earnings beat expectations at $2.33 EPS, though Q4 2025 missed. The company maintains strong profitability with a 55.82% gross margin and 13.22% net margin, while valuation ratios like P/E of 35.64 suggest a premium. A quarterly dividend of $1.02 was declared, payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support growth, but high input costs pressure margins. Risks include competitive threats and valuation concerns. Analyst consensus is cautious with 71.42% hold ratings. Upside hinges on margin stability and execution of clear growth strategies amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
